Cellceutix signs collaborative agreement with Beth

The study will provide insights to exploit the nuclear and/or mitochondrial pro-apoptotic function by Kevetrin in combination with other multikinase inhibitors in treatment of these malignancies, Cellceutix said.

The collaborative studies are independent from the planned clinical trials for Kevetrin that will be conducted at the cancer centers.

Cellceutix chief executive officer Leo Ehrlich said Beth Israel Deaconess Medical Center will be researching Kevetrin for indications in addition to those which the company will be studying in self-sponsored clinical trials.

"If they collect promising data in their research of Kevetrin in melanoma and renal cell carcinoma, additional grant and government funding may become available to further study these separate indications, saving us substantial time and money towards the end goal of commercialization," Ehrlich added.